This website is now the new JPND's archival platform. This website hosts all of JPND's archived content and resources.
Please continue to visit this site to access publications, videos and reports from JPND's activities.
The DOGS+CELLS Trial: A new pathway to treating Alzheimer’s dementia Investments < €500k Australia 2016
Investigating the utility of oxidative stress as a biomarker for cognitive decline and dementia: a longitudinal magnetic resonance imaging study in ‘at risk’ older adults and Alzheimer’s disease. Investments < €500k Australia 2016
Impact of genetics on the effect that modifiable lifestyle factors have on rates of change in Alzheimer’s Disease Investments < €500k Australia 2016
Establishment of Sil1 as a novel drug target for Alzheimer’s disease Investments < €500k Australia 2016
Microvascular breakdown: At the core of plaque formation and neuronal pathology in Alzheimer’s disease Investments < €500k Australia 2016
Understanding how vessel fragility contributes to Alzheimer’s disease Investments < €500k Australia 2016
Restoring Neuroprotective Sphingosine 1-phosphate Signalling in Alzheimer’s Disease Investments < €500k Australia 2016
A randomized controlled trial of Theta Burst Stimulation for the treatment of cogntive impairment in mild to moderate Alzheimer’s disease Investments < €500k Australia 2016
Targeting mitochondrial dysfunction as a potential therapy for the prevention of neurodegenerative disorders including Alzheimer’s Disease (AD) Investments < €500k Australia 2016
Activating the immune system to treat Alzheimer’s disease Investments < €500k Australia 2016
